Metraipolis › archive › dc_3dbcb6db92ac

Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib — Europe PMC PMID:41744860

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41744860
DOI: 10.3390/curroncol33020096
License (as archived): solo-consultazione
Archived: 2026-11-06T03:36:05.569Z
SHA-256 of the archived text: 51b63e707a889dd85981605f8690886b667032b60281ed1eb82b55ca9d7d4b06
Stable URL of this page: https://metraipolis.com/documento/dc_3dbcb6db92ac

How to cite

Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib — Europe PMC PMID:41744860 — Europe PMC (en), https://europepmc.org/article/MED/41744860 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3dbcb6db92ac (Metraipolis archive dc_3dbcb6db92ac, sha256 51b63e707a889dd85981605f8690886b667032b60281ed1eb82b55ca9d7d4b06)

BibTeX

@misc{dc3dbcb6db92ac,
  title = {Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib — Europe PMC PMID:41744860},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41744860},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3dbcb6db92ac; sha256 51b63e707a889dd85981605f8690886b667032b60281ed1eb82b55ca9d7d4b06},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41744860. Agents can read the archived copy with the MCP tool read_document.